APA

Tibes R., McDonagh K. T., Lekakis L., Bogenberger J. M., Kim S., Frazer N., Mohrland S., Bassett D., Garcia R., Schroeder K., Shanmugam V., Carpten J., Hagelstrom R. T., Beaudry C., Von Hoff D. & Shea T. C. (20160119). Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias. : Investigational new drugs.

Chicago

Tibes R, McDonagh K T, Lekakis L, Bogenberger J M, Kim S, Frazer N, Mohrland S, Bassett D, Garcia R, Schroeder K, Shanmugam V, Carpten J, Hagelstrom R T, Beaudry C, Von Hoff D and Shea T C. 20160119. Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias. : Investigational new drugs.

Harvard

Tibes R., McDonagh K. T., Lekakis L., Bogenberger J. M., Kim S., Frazer N., Mohrland S., Bassett D., Garcia R., Schroeder K., Shanmugam V., Carpten J., Hagelstrom R. T., Beaudry C., Von Hoff D. and Shea T. C. (20160119). Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias. : Investigational new drugs.

MLA

Tibes R, McDonagh K T, Lekakis L, Bogenberger J M, Kim S, Frazer N, Mohrland S, Bassett D, Garcia R, Schroeder K, Shanmugam V, Carpten J, Hagelstrom R T, Beaudry C, Von Hoff D and Shea T C. Phase I study of the novel Cdc2/CDK1 and AKT inhibitor terameprocol in patients with advanced leukemias. : Investigational new drugs. 20160119.